Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2010 1
2012 2
2013 3
2014 3
2015 2
2016 1
2017 1
2018 3
2019 2
2020 3
2022 2
2023 6
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

29 results

Results by year

Filters applied: . Clear all
Page 1
Preclinical Efficacy of the Antibody-Drug Conjugate CLDN6-23-ADC for the Treatment of CLDN6-Positive Solid Tumors.
McDermott MSJ, O'Brien NA, Hoffstrom B, Gong K, Lu M, Zhang J, Luo T, Liang M, Jia W, Hong JJ, Chau K, Davenport S, Xie B, Press MF, Panayiotou R, Handly-Santana A, Brugge JS, Presta L, Glaspy J, Slamon DJ. McDermott MSJ, et al. Among authors: o brien na. Clin Cancer Res. 2023 Jun 1;29(11):2131-2143. doi: 10.1158/1078-0432.CCR-22-2981. Clin Cancer Res. 2023. PMID: 36884217 Free PMC article. Clinical Trial.
MDM2 and MDMX promote ferroptosis by PPARα-mediated lipid remodeling.
Venkatesh D, O'Brien NA, Zandkarimi F, Tong DR, Stokes ME, Dunn DE, Kengmana ES, Aron AT, Klein AM, Csuka JM, Moon SH, Conrad M, Chang CJ, Lo DC, D'Alessandro A, Prives C, Stockwell BR. Venkatesh D, et al. Among authors: o brien na. Genes Dev. 2020 Apr 1;34(7-8):526-543. doi: 10.1101/gad.334219.119. Epub 2020 Feb 20. Genes Dev. 2020. PMID: 32079652 Free PMC article.
Targeting the IL1β Pathway for Cancer Immunotherapy Remodels the Tumor Microenvironment and Enhances Antitumor Immune Responses.
Diwanji R, O'Brien NA, Choi JE, Nguyen B, Laszewski T, Grauel AL, Yan Z, Xu X, Wu J, Ruddy DA, Piquet M, Pelletier MR, Savchenko A, Charette L, Rodrik-Outmezguine V, Baum J, Millholland JM, Wong CC, Martin AM, Dranoff G, Pruteanu-Malinici I, Cremasco V, Sabatos-Peyton C, Jayaraman P. Diwanji R, et al. Among authors: o brien na. Cancer Immunol Res. 2023 Jun 2;11(6):777-791. doi: 10.1158/2326-6066.CIR-22-0290. Cancer Immunol Res. 2023. PMID: 37040466
Correction: PP2A inhibition overcomes acquired resistance to HER2 targeted therapy.
McDermott MSJ, Browne BC, Conlon NT, O'Brien NA, Slamon DJ, Henry M, Meleady P, Clynes M, Dowling P, Crown J, O'Donovan N. McDermott MSJ, et al. Among authors: o brien na. Mol Cancer. 2023 Oct 30;22(1):175. doi: 10.1186/s12943-023-01890-z. Mol Cancer. 2023. PMID: 37915024 Free PMC article. No abstract available.
EMP2 Is a Novel Regulator of Stemness in Breast Cancer Cells.
Dillard C, Kiyohara M, Mah V, McDermott SP, Bazzoun D, Tsui J, Chan AM, Haddad G, Pellegrini M, Chang YL, Elshimali Y, Wu Y, Vadgama JV, Kim SR, Goodglick L, Law SM, Patel DD, Dhawan P, O'Brien NA, Gordon LK, Braun J, Lazar G, Wicha MS, Wadehra M. Dillard C, et al. Among authors: o brien na. Mol Cancer Ther. 2020 Aug;19(8):1682-1695. doi: 10.1158/1535-7163.MCT-19-0850. Epub 2020 May 25. Mol Cancer Ther. 2020. PMID: 32451329 Free PMC article.
29 results